Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care
PRNewswire (Wed, 11-Feb 7:00 AM ET)
Labcorp Holdings Adds John Sampson to Board
TipRanks (Mon, 9-Feb 9:00 AM ET)
Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors
PRNewswire (Mon, 9-Feb 8:30 AM ET)
Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026
PRNewswire (Thu, 15-Jan 4:15 PM ET)
Labcorp Declares Quarterly Dividend
PRNewswire (Wed, 14-Jan 6:50 AM ET)
Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk
PRNewswire (Tue, 13-Jan 7:00 AM ET)
Business Wire (Thu, 8-Jan 9:00 AM ET)
PRNewswire (Thu, 8-Jan 8:30 AM ET)
Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference
PRNewswire (Tue, 30-Dec 4:15 PM ET)
Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp
Business Wire (Tue, 2-Dec 4:15 PM ET)
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Labcorp Hldgs trades on the NYSE stock market under the symbol LH.
As of February 12, 2026, LH stock price declined to $278.11 with 806,098 million shares trading.
LH has a beta of 0.37, meaning it tends to be less sensitive to market movements. LH has a correlation of 0.07 to the broad based SPY ETF.
LH has a market cap of $23.08 billion. This is considered a Large Cap stock.
Last quarter Labcorp Hldgs reported $4 billion in Revenue and $4.18 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.05.
In the last 3 years, LH traded as high as $293.72 and as low as $191.97.
The top ETF exchange traded funds that LH belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
LH has outperformed the market in the last year with a price return of +14.6% while the SPY ETF gained +13.8%. LH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.0% and +3.8%, respectively, while the SPY returned 0.0% and -2.0%, respectively.
LH support price is $285.26 and resistance is $294.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LH shares will trade within this expected range on the day.